Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 97.59 | 88.60 | 84.16 | 83.40 | 83.73 | 83.02 | |
| Profit Margin | -47.34 | -43.50 | -69.66 | -158.88 | -189.17 | -712.79 | -705.83 | -869.63 | -545.95 | -1,016.58 | -403.24 | -174.15 | -101.01 | -109.04 | -24.08 | |
| Operating Margin | -47.86 | -44.05 | -66.24 | -194.01 | -197.05 | -800.97 | -720.27 | -900.33 | -556.20 | -1,087.56 | -427.50 | -168.09 | -83.93 | -75.68 | -15.43 | |
|
EPS Growth
|
-78.13 | 8.77 | -30.77 | -55.15 | 31.28 | -234.48 | 28.87 | -38.84 | -13.15 | -39.67 | -7.13 | 8.02 | 3.49 | -29.17 | 62.15 | |
| EPS USD | -114.00 | -104.00 | -136.00 | -211.00 | -145.00 | -485.00 | -345.00 | -479.00 | -542.00 | -757.00 | -811.00 | -746.00 | -720.00 | -930.00 | -352.00 | |
| Return on Assets (ROA) | -9.89 | -11.07 | -20.45 | -36.87 | -21.22 | -33.38 | -20.92 | -32.48 | -24.61 | -48.36 | -37.00 | -25.19 | -23.41 | -31.90 | -11.49 | |
| Return on Equity (ROE) | -26.74 | -27.50 | -48.86 | -79.08 | -33.00 | -38.49 | -22.94 | -44.57 | -27.79 | -58.49 | -61.59 | -84.46 | -144.99 | 714.91 | 199.53 | |
| Return on Invested Capital (ROIC) | -28.03 | -30.31 | -89.40 | -85.12 | -33.01 | -40.05 | -21.28 | -37.01 | -26.23 | -58.47 | -46.58 | -54.05 | -44.72 | -67.81 | -12.91 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | -0.87 | -2.83 | -22.29 | 1.48 | 0.70 | -2.47 | 0.49 | 12.79 | 2.05 | 5.90 | 24.21 | 15.30 | 27.38 | 37.23 | 63.70 | |
| Debt/Equity | -2.35 | -7.03 | -53.26 | 3.17 | 1.08 | -2.85 | 0.53 | 17.55 | 2.32 | 7.13 | 40.31 | 51.29 | 169.60 | -834.42 | -1,105.64 | |
| Debt/EBITDA | 288.58 | 147.80 | 129.36 | 330.79 | 57.21 | -2,412.81 | 432.74 | 10.27 | 123.05 | 46.71 | 25.91 | -3.19 | -25.05 | -50.74 | -819.71 | |
|
Debt/Capitalization
|
-2.41 | -7.56 | -113.97 | 3.07 | 1.07 | -2.93 | 0.53 | 14.93 | 2.27 | 6.66 | 28.73 | 33.90 | 62.91 | 113.62 | 109.94 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | - - | -3.50 | - - | 14.02 | 1.67 | 2.25 | 16.10 | 15.84 | 53.46 | 114.13 | 110.40 | |
| Interest Debt per Share USD | 0.03 | -0.21 | -1.45 | 0.10 | 0.06 | -0.32 | 0.15 | 1.98 | 0.59 | 1.21 | 5.31 | 5.27 | 9.63 | 12.13 | 20.50 | |
| Debt Growth | - - | - - | - - | - - | - - | - - | - - | - - | -80.00 | - - | 912.74 | 71.54 | 91.41 | 32.34 | 103.19 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 265.08 | 160.20 | 1,468.77 | 149.20 | 238.80 | 715.97 | 1,115.55 | 513.65 | 899.06 | 498.00 | 181.29 | 191.47 | 240.81 | 350.59 | 308.20 | |
| Quick Ratio | 259.58 | 106.79 | 815.16 | 80.09 | 166.54 | 709.18 | 1,100.75 | 337.58 | 869.71 | 454.18 | 165.11 | 175.25 | 221.11 | 316.49 | 285.93 | |
| Cash Ratio | 124.14 | 32.22 | 387.14 | 33.50 | 35.40 | 615.32 | 1,051.72 | 100.53 | 325.45 | 173.02 | 57.21 | 44.02 | 68.83 | 112.82 | 83.97 | |
| Operating Cash Flow Ratio | - - | - - | -400 | - - | - - | -100 | -100 | -100 | -100 | -200 | - - | - - | - - | - - | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 7.49 | 44.48 | 84.56 | 114.22 | 130.90 | 348.20 | |
| Receivables Turnover | 1,663.35 | 708.56 | 5,637.40 | 64,158.65 | 1,110.33 | 126.60 | 495.26 | 202.10 | 264.43 | 399.30 | 510.92 | 481.24 | 425.18 | 435.96 | 557.77 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 3.02 | 50.24 | 150.20 | 190.86 | 172.10 | 559.10 | |
|
Asset Turnover
|
20.88 | 25.44 | 29.36 | 23.21 | 11.22 | 4.68 | 2.96 | 3.73 | 4.51 | 4.76 | 9.17 | 14.47 | 23.17 | 29.25 | 47.74 | |
| Fixed Turnover | 548.64 | 547.00 | 565.16 | 337.01 | 286.76 | 232.57 | 147.77 | 41.16 | 49.43 | 23.36 | 34.00 | 69.76 | 115.08 | 140.45 | 251.90 | |
| Coverage | ||||||||||||||||
| Interest Coverage | -893.43 | -1,911.93 | -4,549.21 | -13,250.36 | -8,694.29 | -15,825.71 | -5,052.19 | -5,110.58 | -4,087.02 | -2,784.06 | - - | -980.45 | -495.49 | -503.35 | -232.78 | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | - - | 700 | 6,000 | 4,600 | 500 | 500 | 200 | 100 | - - | |
| Cash Flow Coverage (CFGR) | 1,722.25 | 758.74 | 138.53 | -2,721.49 | -2,347.25 | 621.40 | -2,809.57 | -190.53 | -934.24 | -605.71 | -48.01 | -117.99 | -64.32 | -41.00 | 4.27 | |
| EBITDA Coverage | -800 | -2,100 | -4,500 | -1,500 | -8,600 | 1,400 | -5,000 | -5,100 | -4,000 | -2,800 | - - | -900 | -400 | -500 | -100 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -6.49 | -10.50 | -16.68 | -11.55 | -2.25 | -5.00 | -3.67 | -12.80 | -4.27 | -10.38 | -7.04 | -5.74 | -4.25 | -3.91 | -1.84 | |
|
Price/Earnings (P/E)
|
-1,541.44 | -952.58 | -599.56 | -865.66 | -4,435.67 | -1,999.19 | -2,725.87 | -781.43 | -2,343.76 | -963.11 | -1,420.12 | -1,741.24 | -2,355.34 | -2,556.62 | -5,430.71 | |
| Price/Earnings Growth (PEG) | -19.73 | 108.59 | -19.49 | -15.70 | 141.81 | -8.53 | 94.43 | -20.12 | -178.20 | -24.28 | -199.08 | 217.25 | 675.80 | -87.66 | 87.38 | |
|
Price/Book (P/B)
|
412.20 | 261.96 | 292.92 | 684.59 | 1,463.94 | 769.54 | 625.20 | 348.25 | 651.31 | 563.30 | 874.68 | 1,470.58 | 3,414.96 | -18,277.62 | -10,835.67 | |
| Price/Tangible Book (P/TB) | 412.20 | 261.96 | 292.92 | 684.59 | 1,463.94 | 769.54 | 625.20 | 348.25 | 651.31 | 563.30 | 874.68 | 1,470.58 | 3,414.96 | -18,277.62 | -10,835.67 | |
| Price/Sales (P/S) | 729.68 | 414.34 | 417.66 | 1,375.38 | 8,390.89 | 14,250.05 | 19,239.86 | 6,795.55 | 12,795.72 | 9,790.70 | 5,726.48 | 3,032.29 | 2,379.16 | 2,787.63 | 1,307.68 | |
|
Price/Cash Flow (P/CF)
|
-1,016.80 | -491.47 | -396.98 | -793.81 | -5,764.49 | -4,349.75 | -4,180.50 | -1,041.50 | -3,005.57 | -1,303.56 | -4,519.65 | -2,430.19 | -3,130.30 | -5,342.84 | 22,954.28 | |
| Price/Free CF (P/FCF) | -951.53 | -465.36 | -391.18 | -740.35 | -5,446.69 | -4,126.51 | -3,912.62 | -860.89 | -2,362.42 | -1,063.67 | -3,006.32 | -2,180.69 | -2,797.37 | -4,715.12 | 56,999.06 | |
| Price/Operating CF (P/OCF) | -1,016.80 | -491.47 | -396.98 | -793.81 | -5,764.49 | -4,349.75 | -4,180.50 | -1,041.50 | -3,005.57 | -1,303.56 | -4,519.65 | -2,430.19 | -3,130.30 | -5,342.84 | 22,954.28 |